WY60.F INIFY LABORATORIES AB
- Market cap
- EUR 40.6M
- P/E
- -
- P/B
- 3.26x
- ROE
- -59.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is WY60.F undervalued?
Graham numberThe Graham number of INIFY LABORATORIES AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INIFY LABORATORIES AB fundamental analysis
No fundamental analysis for INIFY LABORATORIES AB yet.
INIFY LABORATORIES AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INIFY LABORATORIES AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.
Full company profileINIFY LABORATORIES AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
INIFY LABORATORIES AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 1.19M | 13.1M | 22.0M | 22.2M |
| Gross Profit | 852K | 11.3M | 18.6M | 18.9M |
| Operating Income | -55.8M | -53.0M | -69.7M | -85.6M |
| EBITDA | -49.0M | -46.9M | -62.9M | -68.9M |
| Net Income | -53.3M | -51.6M | -67.9M | -84.0M |
| EPS | -1.16 | -1.12 | -0.85 | -0.78 |
| Balance Sheet | ||||
| Total Assets | 93.0M | 42.9M | 141M | 157M |
| Total Liabilities | 7.95M | 9.50M | 34.0M | 16.4M |
| Shareholders' Equity | 85.0M | 33.4M | 107M | 140M |
| Cash & Short-term Investments | 70.9M | 22.7M | 57.5M | 72.3M |
| Cash Flow | ||||
| Operating Cash Flow | - | -46.6M | -42.9M | - |
| Capital Expenditure | 0.00 | 1.59M | 62.1M | 0.00 |
| Free Cash Flow | - | -48.2M | -105M | - |
| Ratios | ||||
| ROE | -62.7% | -154.6% | -63.7% | -59.9% |
| ROA | -57.3% | -120.4% | -48.3% | -53.6% |
| Net Profit Margin | -4,469.8% | -393.3% | -308.5% | -377.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INIFY LABORATORIES AB dividends
INIFY LABORATORIES AB has not paid dividends in the last 3 fiscal years.
Who owns INIFY LABORATORIES AB
- Insiders 82.58%
- Institutions 1.36%
- Public & others 16.06%
- Shares outstanding 107M
INIFY LABORATORIES AB company profile
- Company name
- INIFY LABORATORIES AB
- Ticker
- WY60.F
- ISIN
- SE0017486103
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Hollandargatan 13, Stockholm, Sweden, 111 36
- Phone
- 46 08 26 73 30
- Website
- inify.com
About INIFY LABORATORIES AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.
INIFY LABORATORIES AB management
7- Mr. Fredrik PalmChief Executive Officer · born 1975
- Ms. Ann-Charlotte LinderothChief Financial Officer · born 1972
- Emelie EdvigssonChief Operating Officer · born 1983
- Mr. Gunnar LathenChief Technology Officer
- Dr. Claes LindhChief Medical Officer · born 1979
- Ms. Johanna KarlingChief Quality & Regulatory Affairs Officer · born 1963
- Mr. Magnus AurellChief Commercial Officer · born 1964